The "SYK Inhibitors Market, Drug Price, Sales & Clinical Trials Outlook 2030" report has been added to ResearchAndMarkets.com's offering. Report Findings & Highlights: Global SYK Inhibitor Market ...

CORA Loyalty, the loyalty portfolio arm of CORA Group ("CORA"), advises financial institutions to move beyond product-based rewards and adopt enterprise loyalty strategies that recognize and reward ...

Clinical trial evaluating changes in urine protein-to-creatinine ratio, a widely-accepted endpoint measuring risk reduction ...

Findings reinforce brilaroxazine’s treatment effect on negative symptoms and other symptom domains in schizophrenia and support ...

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

A large-scale international study, led by researchers from the Gray Faculty of Medical and Health Sciences at Tel Aviv ...

Discover why Mirum Pharmaceuticals, Inc. stock surged 65%. Explore robust pipeline growth, revenue outlook, and analyst insights. Click for this MIRM update.

Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET -- -- First and only approved option: YARTEMLEA(R) is the only approved treatment for hematopoietic stem cell ...

A large-scale international study, led by researchers from the Gray Faculty of Medical and Health Sciences at Tel Aviv ...

A large-scale international study, led by researchers from the Gray Faculty of Medical and Health Sciences at Tel Aviv University, has uncovered a ...

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with ...

The SYK inhibitor market is poised for rapid growth, driven by increased interest in addressing unmet needs in autoimmune diseases, hematological conditions, and cancer. With ongoing clinical trials ...